X
Top Stories
Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma

Study investigators present a single institution retrospective observational study of adult patients treated with palliative RT for chemotherapy refractory gingival myeloid sarcoma.

Frontiers in Oncology
05/10/2021
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate t

The ASCO Post
05/11/2021

Head And Neck Cancer

Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Given each drug's single agent activity and unique mechanism of action, this study aims to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC.<

The Lancet Oncology
05/11/2021
Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers

This study aims to compare patients with early oral cavity squamous cell carcinoma treated with traditional elective neck dissection with those managed by sentinel lymph node biopsy using...

Journal of Clinical Oncology
04/20/2021
Research Progress of circRNAs in Head and Neck Cancers

In this study, the generation, characteristics, and functions of circRNAs, along with their regulatory mechanisms in head and neck cancers are summarized.

Frontiers in Oncology
04/29/2021
Effect of Acupuncture in Pain Management of Head and Neck Cancer Radiotherapy

This prospective randomized open-label trial evaluates the role of acupuncture in the treatment of pain related to curative and adjuvant (chemo)radiotherapy of head and neck cancer.

Journal of Clinical Medicine
03/07/2021
The Potential of MET Immunoreactivity for Prediction of Lymph Node Metastasis in Early Oral Tongue Squamous Cell Carcinoma

Since MET is a known orchestrator of invasive tumor growth, study investigators examine its association with LNM in early oral tongue squamous cell carcinoma.

Frontiers in Oncology
04/29/2021

FDA Approvals

FDA Clears IND Application for CAR-Natural Killer Cell Therapy to Treat B-Cell Malignancies

The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with R/R B-cell malignancies.

Healio
05/03/2021
FDA ODAC Votes in Favor of Maintaining Accelerated Approval of Atezolizumab/Nab-paclitaxel for PD-L1–Positive, Metastatic Triple-Negative Breast Cancer

The FDA ODAC voted seven to two in favor of maintaining accelerated approval of atezolizumab in combination with CT for the treatment of adults with unresectable locally advanced or metastatic TNBC

The ASCO Post
04/28/2021
FDA Grants Breakthrough Therapy Designation to Asciminib for CML

The FDA has granted breakthrough therapy designation to asciminib for the treatment of adults with Philadelphia chromosome-positive chronic-phase CML that is resistant to...

ASH Clinical News
04/01/2021
FDA Panel Votes Against Two Cancer Indications But Backs 4 of 6

 

The staff of the FDA will now consider these votes as they decide what to do regarding the six cases of what they have termed "dangling" accelerated approvals.

Medscape
04/30/2021
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer

The FDA approves pembrolizumab in combination with trastuzumab plus fluoropyrimidine- and platinum-containing CT for the first-line treatment of patients with locally advanced unresectable or metas

The ASCO Post
05/05/2021
FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas

The FDA grants an accelerated approval for a new drug for use in patients with R/R DLBCL who have tried at least two prior systemic therapies.

Medscape
04/26/2021

Oncology

Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center.

Translational bioinformatics for therapeutic discovery requires the infrastructure of clinical informatics.

Methods of Molecular Biology
01/01/2021
Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.

Jehovah's Witnesses undergoing liver or pancreas surgery represent a unique medical and ethical challenge.

Cancer medicine journal
04/01/2021
Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy

Major developments in drugs such as thiopurines and optimization in clinical trial protocols for treating cancer in children have led to a remarkable improvement in survival, from approximately...<

Annual Review of Pharmacology and Toxicology
01/06/2021
Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective.

This study aimed to select the most promising IG technology per oncologic indication.

Journal of Surgical Research
01/01/2021
The use of Hericium erinaceus and Trametes versicolor extracts in supportive treatment in oncology.

Substances available in nature with potential therapeutic effects are the subject of research that raises tremendous hopes for new challenges medicine.

Acta Pharmaceutica
03/01/2021

Lung Cancer

Understanding Socioeconomic Disparities in Lung Cancer Care

A recent study finds that sociodemographic factors such as race, marital, income, and insurance status are associated with disparities in the receipt of lung cancer treatment, per findings...

Oncology Times - Latest Articles
04/01/2021
The Impact of the COVID-19 Pandemic on Lung Cancer Screening

According to Dr. Norman Sharpless, the decrease in low-dose CT scanning for lung nodules and subsequent increased number of suspicious pulmonary nodules have become particularly alarming.

Oncology Times - Latest Articles
04/20/2021
Exploring Prescribing Patterns in Lung Cancer Patients at the End of Life

A recent study finds that more than 10 percent of lung cancer patients received some treatment in the last 30 days of life, according to data presented at the NCCN 2021 Virtual Annual Conference.

Oncology Times - Latest Articles
04/01/2021
RNA-Based Therapies: A Cog in the Wheel of Lung Cancer Defense

This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies...

Molecular Cancer
03/19/2021
Researchers Uncover a Potential Treatment for Aggressive Form of Lung Cancer

These findings could pave the way for new treatments for patients with mutations in two key genes—KRAS and LKB1. 

Oncology Times - Latest Articles
04/01/2021

Immuno Oncology

Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
04/10/2021
mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
03/03/2021
Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles
04/05/2021
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
02/26/2021
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
03/01/2021

Gastrointestinal Cancer

Esophageal Cancer: Preop Chemoradiotherapy Benefit for 10 Years

Among patients with locally advanced resectable esophageal or junctional cancer, the overall survival benefit conferred by preoperative chemoradiotherapy persists for at least 10 years.

Medscape
05/13/2021
Retrieval of 30 Lymph Nodes Is Mandatory for Selected Stage II Gastric Cancer Patients

This study aims to explore the impact of retrieving 30 or more lymph nodes on the survival of stage II cancer patients.

Frontiers in Oncology
04/30/2021
Hepatic Metastasis in Newly Diagnosed Esophageal Cancer

The primary objective of this study is to explore the predictors of esophageal cancer with hepatic metastasis at the time of diagnosis. 

Frontiers in Oncology
05/10/2021
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

This study aims to answer the question do older and/or frail patients with advanced gastroesophageal cancer benefit from less intensive palliative CT, and can a formal geriatric assessment assist..

JAMA Oncology
05/13/2021
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer

The multicenter VARIANZ study aims to investigate the background of response and resistance to trastuzumab in mGC.

Journal of Clinical Oncology
03/25/2021

Skin Cancer

Construction and Validation of a Nomogram for Patients With Skin Cancer

Study investigators use patient data collected from the surveillance, epidemiology, and end results program database to construct and validate the model for clinical prediction of skin cancer.

Medicine
01/29/2021
Health-Related Quality of Life With Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma

An analysis of this trial shows no clinically significant decline in health-related quality of life with adjuvant pembrolizumab vs placebo in resected high-risk stage III melanoma. 

The ASCO Post
04/28/2021
Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma

Current guidelines for postoperative management of patients with stage I-IIA cutaneous melanoma do not recommend routine cross-sectional imaging...

JCO Precision Oncology
04/06/2021
Patterns in the Development of Melanoma Across Body Sites

An international research team examined patterns in the development of melanoma in patients in Australia and the United Kingdom and shed light on possible relationships by anatomical site.

Cancer Therapy Advisor
03/24/2021
Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing

In this study, tumor tissue samples are collected from 64 CMM patients.

Frontiers in Oncology
04/29/2021

Gynecologic Cancer

Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

This study evaluates the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate, in this patient population.

The Lancet Oncology
05/01/2021
Tisotumab for Advanced Cervical Cancer Awaiting Approval

Tisotumab vedotin, an investigational antibody drug conjugate directed against tissue factor, has shown promise for patients with recurrent or metastatic cervical cancer.

Medscape
04/20/2021
Adjuvant Therapy Benefit Questioned in POLE-Mutated Endometrial Cancer

An individual patient data meta-analysis failed to demonstrate that receipt of adjuvant therapy provided a clear benefit for women with POLE-mutated endometrial cancer.

Cancer Therapy Advisor
04/27/2021
Outcomes With MRI-Based Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer

In this study, Pötter et al find that MRI-based image-guided adaptive brachytherapy is associated with a high rate of long-term local disease control and...

The ASCO Post
04/16/2021
Study Finds Ixabepilone Plus Bevacizumab Active in Platinum-Resistant or Recurrent Ovarian Cancer

The addition of bevacizumab to ixabepilone could be a promising treatment strategy for a group of patients with cancer currently lacking therapeutic options, according to data presented during the

The ASCO Post
05/12/2021
In Gynecologic Cancers, Who Can Safely Undergo Fertility-Sparing Surgery?

Traditional surgeries for gynecologic cancers can be lifesaving, but for younger women they can also cause infertility or induce surgical menopause.

Oncology Times - Latest Articles
04/20/2021
Spotlight
Hepatic Metastasis in Newly Diagnosed Esophageal Cancer

The primary objective of this study is to explore the predictors of esophageal cancer with hepatic metastasis at the time of diagnosis. 

Frontiers in Oncology
05/10/2021

News

Normal Basal Epithelial Cells Stimulate the Migration and Invasion of Prostate Cancer Cell RM-1 by TGF-β1/STAT3 Axis in vitro

This study aims to investigate whether basal epithelial cells could suppress migration and invasion of prostate cancer cells to become a new treatment strategy for prostate cancer.

Cancer Management and Research
05/07/2021
9006
Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach

A remarkable evolution in the treatment of mCSPC has been noted in the previous several years.

OncoTargets and Therapy
05/05/2021
9005
Primary Breast Tumors Often Switch HER2 Status on Relapse

A substantial proportion of primary breast tumors that are HER2 negative (HER2-0) switch to showing HER2-low expression upon relapse, a first-of-its-kind study suggests.

Medscape
05/11/2021
8973
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Given each drug's single agent activity and unique mechanism of action, this study aims to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC.

The Lancet Oncology
05/11/2021
8975
Understanding Socioeconomic Disparities in Lung Cancer Care

A recent study finds that sociodemographic factors such as race, marital, income, and insurance status are associated with disparities in the receipt of lung cancer treatment, per findings...

Oncology Times - Latest Articles
04/01/2021
8976
MicroRNA-383-5p Predicts Favorable Prognosis and Inhibits the Progression of Diffuse Large B-Cell Lymphoma

The present study aims to investigate the role of miR-383-5p in DLCBL. 

Oncology Letters
05/06/2021
8986

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39

Trending

1
MicroRNA-383-5p Predicts Favorable Prognosis and Inhibits the Progression of Diffuse Large B-Cell Lymphoma
Oncology Letters
2
Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer
The Lancet Oncology
3
Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation
Cancer Management and Research